13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001710065
Total reported value
—
$22.8M
7 檔
97.3%
During the Q4 2025 filing period, AJU IB Investment Co., Ltd. (CIK: 0001710065) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $22.8M across 7 reported positions.
In Q4 2025, AJU IB Investment Co., Ltd. adopted a defensive or profit-taking posture, trimming 3 positions and completely liquidating 0 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ACLXGBX | Arcellx Inc | Stock-Other | 63.94% | -84.07% | EXIT | |
| 2 | ✓ | Rallybio CORP | Stock-Other | 18.18% | — | — | |
| 3 | KYMR | Kymera Therapeutics Inc | Stock-Other | 6.71% | -5.36% | EXIT | |
| 4 | SEER | Seer Inc | Stock-Other | 6.56% | -5.06% | EXIT | |
| 5 | ✓ | Xilio Therapeutics Inc | Stock-Other | 1.88% | — | — | |
| 6 | ✓ | Rapt Therapeutics Inc | Stock-Other | 1.85% | — | — | |
| 7 | STRO | Sutro Biopharma, Inc. | Stock-Other | 0.89% | -1.43% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ✓ | Rallybio CORP | +17.9% | — | Unchanged |
| 2 | SEER | Seer Inc | +5% | — | Unchanged |
| 3 | ✓ | Rapt Therapeutics Inc | +1.6% | — | Unchanged |
| 4 | ✓ | Xilio Therapeutics Inc | +1.4% | — | Unchanged |
| 5 | STRO | Sutro Biopharma, Inc. | +0.8% | -90.00% | Trim |
| 6 | ACLXGBX | Arcellx Inc | -10.8% | -78.67% | Trim |
| 7 | KYMR | Kymera Therapeutics Inc | -15.8% | -95.70% | Trim |
According to official SEC Form 13F filings, AJU IB Investment Co., Ltd. reported a total U.S. public equity portfolio value of $22.8M across 7 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ACLXGBX, RALLYBIO CORP, KYMR) accounted for 97.3% of total reported equity market value during Q4 2025.
Top Position Liquidated / Trimmed
ACLXGBX
前期市值: $86.0M
During Q4 2025, AJU IB Investment Co., Ltd.'s top holdings by market value included ACLXGBX (63.9%)、RALLYBIO CORP (18.2%)、KYMR (6.7%). The largest single position, ACLXGBX, represented 63.9% of total portfolio value.
In Q4 2025, AJU IB Investment Co., Ltd. made 3 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 3 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.